bioAffinity Technologies reports 100% sales growth for CyPath Lung test

Go back to bioAffinity Technologies reports 100% sales growth for CyPath Lung test

bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026

October 6, 2026 9:19 AM EDT

Nearly 90% increase in number of physician offices using CyPath Lung

Utilization expands as physicians who ordered CyPath Lung in 2025 increase usage by nearly 50%

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early... More